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OBJECTIVE—We tested the primary hypotheses that sphingo-
lipid and diacylglycerol (DAG) content is higher within insulin-
resistant muscle and that the association between intramyocellular
triglycerides (IMTG) and insulin resistance is muscle ﬁber type
speciﬁc.
RESEARCH DESIGN AND METHODS—A nested case-con-
trol analysis was conducted in 22 obese (BMI 30 kg/m
2) women
who were classiﬁed as insulin-resistant (IR; n  12) or insulin-
sensitive (IS; n  10), determined by hyperinsulinemic-euglyce-
mic clamp (30% greater in IS compared with IR, P  0.01).
Sphingolipid and DAG content was determined by high-perfor-
mance liquid chromatography–tandem mass spectrometry. Fiber
type–speciﬁc IMTG content was histologically determined. Gene
expression was determined by quantitative PCR.
RESULTS—Total (555  53 vs. 293  54 pmol/mg protein, P 
0.004), saturated (361  29 vs. 179  34 pmol/mg protein, P 
0.001), and unsaturated (198  29 vs. 114  21 pmol/mg protein,
P  0.034) ceramides were higher in IR compared with IS. DAG
concentrations, however, were similar. IMTG content within type
I myocytes, but not type II myocytes, was higher in IR compared
with IS subjects (P  0.005). Insulin sensitivity was negatively
correlated with IMTG within type I myocytes (R  0.51, P 
0.026), but not with IMTG within type II myocytes. The propor-
tion of type I myocytes was lower (41 vs. 59%, P  0.01) in IR
subjects. Several genes involved in lipid droplet and fatty acid
metabolism were differentially expressed in IR compared with IS
subjects.
CONCLUSIONS—Human skeletal muscle insulin resistance is
related to greater IMTG content in type I but not type II
myocytes, to greater ceramide content, and to alterations in gene
expression associated with lipid metabolism. Diabetes 59:
80–88, 2010
S
keletal muscle insulin resistance is a key factor in
the development of type 2 diabetes, although the
exact mechanisms that underlie insulin resis-
tance in humans remain elusive. Considerable
efforts have been made in the past several decades to
better understand the role of impaired fatty acid metabo-
lism in skeletal muscle insulin resistance (1,2). Many
earlier studies, both in animal models (3) and in humans
(4,5), indicated that intramyocellular triglyceride (IMTG)
accumulation was associated with insulin resistance,
thereby providing a potential link between dysregulated
fatty acid metabolism and insulin resistance. However, it
has become increasingly apparent that IMTGs do not
directly confer insulin resistance but rather, under certain
circumstances, likely provide a surrogate for other bioac-
tive lipid metabolites within muscle such as sphingolipids
(including ceramide) and diacylglycerol (DAG) (4,6).
Studies in animal and cell culture models indicate that
sphingolipids and DAG can be key mediators of insulin
resistance (7–9). However, a recent study of acute hyper-
lipidemia in rodents indicates that ceramide and DAG
content are not associated with muscle insulin resistance
(10). Furthermore, studies conducted in humans do not
provide a ﬁrm consensus as to whether ceramides or
DAGs are associated with muscle insulin resistance (11).
Some studies indicate that muscle ceramide content is
elevated in obese compared with lean individuals (12,13),
or that increases in muscle ceramide content as a result of
lipid infusion (14), or conjugated linoleic acid supplemen-
tation (15), were associated with decreased insulin sensi-
tivity. Endurance training in obese subjects reduced
muscle ceramide content with a concomitant improve-
ment in insulin sensitivity (16,17). In contrast, a recent
study by Skovbro et al. (18) found that total muscle
ceramide content was similar in subjects despite a wide
range of insulin sensitivity. Also refuting a role for cer-
amide in human muscle insulin resistance, Itani et al. (19)
reported that lipid-induced insulin resistance did not alter
ceramide content.
The role of muscle DAG content in insulin resistance is
also unclear. Muscle DAG content has been shown to be
elevated in obese and type 2 diabetic subjects (20) and
increased after a 6-h lipid infusion that reduced insulin
sensitivity (19). In contrast, IMTG, but not DAG content in
muscle, was reported to be elevated in obese diabetic
compared with obese nondiabetic subjects (21). There-
fore, to help address the controversy in the literature
surrounding the role for speciﬁc lipid metabolites in
insulin resistance, we conducted comprehensive mass
spectrometry–based DAG and sphingolipid proﬁling in
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factors well known to inﬂuence insulin sensitivity—
namely obesity and physical activity.
Quantiﬁcation of intramyocellular lipids in humans is
further complicated by a heterogeneous myocyte or ﬁber
composition. Type I myocytes have a greater capacity for
oxidative phosphorylation (22,23) and typically can con-
tain two to three times more IMTG than type II myocytes
(22,24,25). Furthermore, type I myocytes have been re-
ported to be more insulin sensitive than type II myocytes
(26,27). However, it is not clear whether insulin sensitivity
is related to differences in myocyte-speciﬁc IMTG content,
nor is it known whether sphingolipid or DAG content is
related to muscle cell type. We tested the primary hypoth-
eses that sphingolipid and DAG content is higher within
insulin-resistant muscle and that type I myocyte IMTG
content is speciﬁcally related to insulin resistance. We also
explored whether differences in the expression of several
genes related to lipid metabolism could play a role in
insulin resistance associated with IMTG accumulation.
RESEARCH DESIGN AND METHODS
Subjects for this nested case-controlled study were selected from ongoing
clinical investigations of skeletal muscle insulin resistance. Only female
subjects were included to provide a sex-controlled analysis. Women aged
60–75 years were recruited through advertisements in the Pittsburgh, PA,
area. A brief phone screening initially determined eligibility for study partic-
ipation. Potential subjects who were determined to be sedentary (exercise 1
day/week), weight stable (3 kg in the previous 6 months), with a BMI 30
kg/m
2, and nonsmokers were further evaluated at the Clinical Translational
Research Center (CTRC) at the University of Pittsburgh. Exclusionary criteria
included uncontrolled hypertension (150/95 mmHg), anemia (hematocrit
34%), elevated liver enzymes (25% above normal), proteinuria, or hypothy-
roidism (sensitive thyroid-stimulating hormone [TSH] 8 mIU/l). Potential
subjects were also excluded if they reported taking chronic medications
known to affect glucose homeostasis. After the medical screening, potential
subjects then completed a 2-h 75-g oral glucose tolerance test to determine
glucose tolerance status. Subjects with type 2 diabetes determined by fasting
glucose 126 mg/dl were excluded. All subjects gave written consent to the
protocol, which was approved by the University of Pittsburgh’s Institutional
Review Board.
Insulin sensitivity. Insulin sensitivity was determined by a 4-h hyperinsu-
linemic (40 mU  m
2  min
1) euglycemic clamp and [6,6-
2H2]glucose infusion
as previously described (28). Brieﬂy, subjects reported to the CTRC the
evening before the clamp and after a 48-h period, in which they refrained from
any vigorous physical activity. A continuous intravenous infusion of insulin
(Humulin; Eli Lilly, Indianapolis, IN) was begun at 7:00 A.M., and euglycemia
(target 90 mg/dl) was maintained using an adjustable infusion of 20% dextrose.
To measure rate of insulin-stimulated glucose disposal and residual endoge-
nous glucose production, a primed (0.22 mol/kg) continuous (17.6 mol 
kg
1  min
1) infusion of [6,6-
2H2]glucose was administered (29). [6,6-
2H2]glucose enrichment in plasma was determined by gas chromatography/
mass spectrometry (6890 Network/5973 Series; Agilent, Santa Clara, CA) as
previously described (30). Plasma glucose was measured by the glucose
oxidase method (2300 Stat Plus; Yellow Springs Instruments, Yellow Springs,
OH). Fasting plasma insulin concentration was determined by an enzyme-
linked immunosorbent assay (Millipore, Billerica, MA). Rate of glucose
disposal (Rd) was calculated using the tracer:tracee method with a modiﬁed
version of the Steele et al. equation (31).
Muscle biopsy. Percutaneous muscle biopsy samples were obtained in the
fasted state before the glucose clamp, as described previously (32). Brieﬂy,
muscle biopsies were obtained from the vastus lateralis, 15 cm above the
patella. A portion of the specimen (30 mg) was snap-frozen in liquid nitrogen
and stored at 80°C for sphingolipid and diacylglycerol analysis. A second
portion (20 mg) was snap-frozen and stored at 80°C for gene expression
analysis. A third portion of the specimen for histochemistry was mounted on
a small piece of cork with mounting medium (Shandon Cryochrome; Thermo
Electron, Pittsburgh, PA), frozen in isopentane cooled with liquid nitrogen for
2–3 min (160°C), and then placed into liquid nitrogen. All samples were
stored at 80°C until analysis.
Analysis of sphingolipid and diacylglycerol species. Brieﬂy, liquid nitro-
gen–frozen samples (30 mg) were homogenized in ice-cold buffer (250
mmol/l sucrose, 25 mmol/l KCl, 50 mmol/l Tris, and 0.5 mmol/l EDTA, pH 7.4).
Total content as well as the various molecular species of diacylglycerol and
sphingolipid were measured by high-performance liquid chromatography–
tandem mass spectrometry as previously described in detail (33).
Analysis of nonesteriﬁed plasma free fatty acids. Plasma free fatty acid
concentrations were determined by gas chromatography with ﬂame ionization
detection (6890N; Agilent, Santa Clara, CA) using heptanoic acid as an internal
standard. Free fatty acids were derivatized with dimethylamine using Deoxo-
Fluor reagent (Sigma-Aldrich, St. Louis, MO).
Histochemical analysis for ﬁber type and IMTG content. Histochemical
analysis was performed on serial sections using a modiﬁed version of methods
previously used in our laboratory (32). Brieﬂy, mounted biopsy samples were
sectioned (10 m) on a cryostat (Cryotome E; Thermo Shandon, Pittsburgh,
PA) at 20°C and placed on a glass slide. Sections were then stained in a
ﬁltered solution of Oil Red O (300 mg/ml in 36% triethylphosphate) for 30 min
at room temperature. Thereafter, sections were incubated with primary
antibodies for anti-human myosin heavy chain (MYH)-7 (type I myocytes) and
MYH2 (type IIa myocytes) overnight at room temperature and subsequently
incubated with ﬂuorescein (FITC) (type IIa myocytes) and rhodamine (type I
myocytes) conjugated secondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA). Type IIx ﬁbers remained unstained. Images were visualized using
a Leica microscope (Leica DM 4000B; Leica Microsystems, Bannockburn, IL),
digitally captured (Retiga 2000R camera; Q Imaging, Surrey, Canada), and
analyzed using specialized software (Northern Eclipse, v6.0; Empix Imaging,
Cheektowaga, NY). Oil red O staining intensity and cross-sectional area were
determined in type I and type II myocytes. Analysis is based on 200 ﬁbers per
section (range 130–350).
Gene expression analysis. Gene expression analysis was carried out in a
subset of subjects from each group, based on availability of vastus lateralis
biopsy specimen (six IR and six IS). Total RNA was isolated using Trizol
reagent (Invitrogen, Carlsbad, CA). Isolated RNA was then further puriﬁed
using a silicon-membrane spin column including an on-column DNase I
treatment (Qiagen, Valencia, CA). Total RNA was reverse-transcribed using
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (SABio-
sciences, Frederick, MD). Gene expression was determined by quantitative
real-time PCR (qRT-PCR) using SYBR green-based custom RT
2 Proﬁler PCR
Arrays (SABiosciences, Frederick, MD). qRT-PCR was performed on an ABI
prism 7900 (Applied Biosystems, Foster City, CA). Baseline, threshold cycle
(Ct) and threshold were determined and set for all samples. The relative level
of mRNA expression for each gene in each sample was normalized to the
average expression of 2-microglobulin, hypoxanthine phosphoribosyltrans-
ferase (HPRT1), glyceraldehydes-3-phosphate dehydrogenase (GAPDH), and
-actin (ACTB) and expressed as 2
	Ct.
Body composition and peak aerobic capacity. Total body fat and lean mass
were assessed using dual-energy X-ray absorptiometry (GE Lunar Prodigy and
Encore 2005 software v9.3). Subjects performed a VO2 peak test on an
electronically braked cycle ergometer to determine aerobic ﬁtness (Sensor
Medics, Yorba Linda, CA) as previously described (34).
Statistical analysis. Group comparisons were made by an independent
two-tailed Student’s t test. Correlations between variables were determined by
Person’s correlation coefﬁcient. All data are means  SE unless otherwise
stated. Statistical signiﬁcance was set at P  0.05.
RESULTS
Ten insulin-sensitive (IS) and 12 insulin-resistant (IR)
women were matched for age, body mass, BMI, and
physical ﬁtness (VO2 peak) (Table 1). There was no
signiﬁcant group difference in fasting plasma glucose,
insulin, or free fatty acid levels. However, by design, Rd
during the hyperinsulinemic-euglycemic clamp was
greater (P  0.01) in the IS group when compared with the
IR group (Table 1). The 2-h plasma glucose levels during
the oral glucose tolerance test were also signiﬁcantly
higher in the IR group compared with the IS group (P 
0.016). The IR (n  6) and IS (n  6) subgroups for gene
expression analysis had similar characteristics as their
respective groups overall (data not shown).
Muscle ﬁber distribution. Type I and II myocyte content
and myocyte average cross-sectional area are presented in
Table 2. The IS group had a higher proportion of type I
myocytes (P  0.002) and a lower proportion of type IIa
(P  0.014 and type IIx (P  0.02) than the IR group. When
data from both groups were combined, there was a higher
proportion of type IIa compared with type IIx myocytes
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average cross-sectional area. With both groups combined,
there was a signiﬁcant positive correlation between the
proportion of type I myocytes and insulin sensitivity and a
negative correlation between the proportion of type II
myocytes (type IIa and IIx combined) and insulin sensitiv-
ity (Table 3).
Muscle content of sphingolipid and diacylglycerol.
The data for muscle content of sphingolipid and diacyl-
glycerol species is presented in Fig. 1. We observed higher
total levels of ceramide (555  53 vs. 293  54 pmol/mg
protein, P  0.004), total unsaturated ceramide (198  29
vs. 114  21 pmol/mg protein, P  0.034), and total
saturated ceramide (361  29 vs. 179  34 pmol/mg
protein, P  0.001) in the IR group compared with the IS
group. We also observed higher levels of speciﬁc ceramide
species containing the following fatty acids: myristic
(C14:0) (4.0  0.8 vs. 1.9  0.4 pmol/mg protein, P 
0.044), palmitic (C16:0) (58  14 vs. 18  5 pmol/mg
protein, P  0.023), and stearic (C18:0) (72  10 vs. 40 
7 pmol/mg protein, P  0.02) in IR compared with IS
muscle. There also tended to be greater content of sphin-
golipids containing palmitoleic (C18:1) (43  11 vs. 19  3
pmol/mg protein, P  0.077) and lignoceric (C24:0) (201 
25 vs. 123  29 pmol/mg protein, P  0.06) acids and
sphingosine (3.4  0.6 vs. 2.2  0.3 pmol/mg protein, P 
0.08) in IR muscle. When data were combined from both
groups, we observed a signiﬁcant negative correlation
between total unsaturated, total saturated, and total cer-
amide content and insulin sensitivity (Table 3). Total
ceramide (R  0.517, P  0.05) and total saturated
ceramide (R  0.523, P  0.05) were positively correlated
with type II myocyte percentage. However, no signiﬁcant
differences in total or individual diacylglycerol species
were observed between IS and IR subjects.
Myocyte-speciﬁc IMTG content. Type I and II myocyte–
speciﬁc IMTG content are shown in Fig. 2. Total muscle
IMTG was greater in the IR group compared with the IS
group (P  0.009). Type I myocyte–speciﬁc IMTG content
was also greater in the IR group compared with the IS
group (P  0.005). There was no difference in type II
myocyte–speciﬁc IMTG content between IS and IR groups,
nor was IMTG content different in IR within subtypes of
type IIa and type IIx myocytes. When both groups were
combined, we observed a signiﬁcant negative correlation
between type I myocyte IMTG content and insulin sensi-
tivity, whereas there was no relationship between insulin
sensitivity and type II myocyte (type IIa and IIx combined)
IMTG content (Fig. 2).
Muscle gene expression. The gene expression data for
IR and IS subgroups is presented in Fig. 3. Expression
levels of key genes, including facilitated GLUT member 4
(GLUT4), insulin receptor substrate (IRS)-1, and IRS2
were lower in the IR group, indicating insulin resistance in
this group at the tissue level in accord with their insulin
resistance assessed in vivo. The expression of genes
relating to oxidative phosphorylation transcription fac-
tors, fatty acid metabolism, ceramide metabolism, and
lipid droplet associated proteins were examined. We
found lower expression of the transcription factors perox-
isome proliferator–activated receptor (PPAR)-
 and
PPAR- in the IR group compared with the IS group. Also,
expression of PPAR- coactivator 1
 (PGC-1
) and nu-
clear respiratory factor 1 (NRF1) tended to be lower in IR
muscle. Furthermore, we observed a lower expression of
carnitine palmitoyltransferase 1B (CPT1B) and malonyl-
CoA decarboxylase (MLYCD), genes that are related to
fatty acid metabolism. Gene expression of lipid droplet–
associated proteins hormone-sensitive lipase (HSL), adi-
pose differentiation–related protein (ADRP), adipose
triglyceride lipase (ATGL), and synaptosomal-associated
protein 23 (SNAP23) was lower in the IR group compared
with the IS group. Interestingly, the expression of genes
relating to ceramide metabolism was not different between
groups. The expression of tumor necrosis factor (TNF)-

tended to be higher in the IR group compared with the IS
group (P  0.09).
TABLE 1
Group characteristics
IS group IR group
n 10 12
Age (years) 64.5  1.4 66.7  0.8
Body mass (kg) 81.1  3.0 81.7  2.5
BMI (kg/m
2) 30.3  1.1 31.3  0.9
VO2peak (ml  kg
1 body
wt  min
1) 15.8  1.1 15.5  1.0
Fasting plasma insulin (mU/ml) 3.7  0.5 6.5  1.3
Fasting plasma glucose (mg/dl) 94.1  5.1 96.7  5.0
Fasting plasma free fatty acids
(mol/l) 502.4  41.2 543.3  41.7
Oral glucose tolerance test
glucose at 120 min (mg/dl) 122  10 164  12*
Rd (ml  kg
1 fat-free
mass  min
1) 10.2  0.3 7.1  0.4*
Data are means  SE. *Signiﬁcantly different from IS group, P  0.05.
TABLE 2
Muscle ﬁber type distribution and surface area in vastus lateralis
muscle
IS group IR group
Type I myocyte content (%) 59  3.9 41  2.5*
Type II myocyte total content (%) 40.5  3.9 58  2.9*
Type IIa myocyte content (%)† 24  2.7 34  1.9*
Type IIx myocyte content (%)† 14  2.5 25  3.4*
Type I myocyte average area (m
2) 5,732  317 5,104  417
Type II myocyte average area (m
2) 4,217  348 4,027  375
Data are means  SE. *Signiﬁcantly different from IS group, P  0.05.
†Data generated from analysis of subgroup (IR, n  10; IS, n  5).
TABLE 3
Correlation of rate of glucose disposal (ml  kg
1 fat-free mass 
min
1) with other study variables when data from both IR and IS
groups were combined
Pearson
correlation coefﬁcient
Type I myocyte content (%) 0.608*
Type II myocyte total content (%) 0.724*
Total ceramide (pmol/mg protein) 0.563*
Total saturated ceramide (pmol/mg
protein) 0.567*
Total unsaturated ceramide (pmol/mg
protein) 0.438†
Total diacyglyceride (pmol/mg protein) 0.006
ADRP gene expression (2
-	Ct) 0.810*
*Correlation is signiﬁcant at the level P  0.01. †Correlation is
signiﬁcant at the level P  0.05.
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Despite a preponderance of evidence from cell culture and
animal models suggesting a role for both ceramide and
diacylglycerol in skeletal muscle insulin resistance (7,8),
there is actually no consensus as to whether this is
relevant to human insulin resistance (12,13,15,17,19). This
study was conducted for three purposes: 1) to determine
whether diacylglycerol or sphingolipid species are ele-
vated in IR human skeletal muscle, 2) to investigate
whether the associations between intramyocellular lipids
are dependent on muscle ﬁber type, and 3) to explore
whether the skeletal muscle expression of several key
genes relating to lipid metabolism are altered in IR muscle
corresponding to intramyocellular lipid content.
A primary ﬁnding of our study was that total as well as
saturated and unsaturated ceramide content was approx-
imately twofold higher in IR skeletal muscle in human
subjects independent of obesity, physical ﬁtness, and
plasma free fatty acid concentration. These results extend
the ﬁndings of Adams et al. (13), who observed elevated
ceramide content in skeletal muscle of obese subjects.
Studies by Straczkowski et al. (12,14) also found that
ceramide accumulation in skeletal muscle was inversely
related to insulin sensitivity. They also suggested that
higher ceramide content in lean offspring of patients with
type 2 diabetes was due to decreased ceramide degrada-
tion, whereas IR of obesity was caused by an increase in
de novo ceramide synthesis (12,14). Not all studies, how-
ever, have observed an association between muscle cer-
amide content and insulin resistance (18,19). These
discrepant results could be attributed to differences in the
subject population studied, e.g., age, sex, physical activity,
and methodological differences, in assessing ceramide
content and insulin sensitivity (11). Thus, our study pro-
vides important new information about the relationship
between elevated ceramide content and muscle insulin
resistance. This is the ﬁrst to a comprehensive proﬁle of
the content of the various molecular species of ceramide
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FIG. 1. Sphingolipid (A) and diacylglycerol (B) content in vastus lateralis of IR and IS subjects. IR data are expressed relative to IS group, which
was set to a value of 1. *Signiﬁcantly different from IS group, P < 0.05. sat, saturated; unsat, unsaturated.
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while controlling for obesity, physical ﬁtness, and age.
This is the ﬁrst study to demonstrate elevated levels of
both saturated and unsaturated ceramides, as well as
speciﬁc ceramides containing C14:0, C16:0, and C18:0 fatty
acids in IR human muscle.
None of the prior studies examining ceramide in human
muscle have accounted for heterogeneity in muscle type
that could account for differences in insulin sensitivity.
Our novel ﬁnding that ceramide content was associated
with a higher percentage of type II myocytes suggests that
ceramide accumulation may be ﬁber-type dependent. Fur-
ther investigation is needed to conﬁrm this. In addition,
the complementary observations that both the IMTG con-
tent in type I myocytes and the lower proportion of type I
myocytes are related to insulin resistance provide insight
into muscle heterogeneity in lipid metabolism in insulin
resistance. These data suggest a possibility that type I
myoﬁbers may have a greater capacity to buffer increases
in free fatty acids by partitioning to lipid droplet IMTG,
whereas type II ﬁbers have a reduced capacity to incorpo-
rate excess fatty acids into IMTG and are more inclined to
partition to lipotoxic mediators such as ceramide species.
An impairment of skeletal muscle oxidative capacity has
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FIG. 2. Myocyte-speciﬁc IMTG content in vastus lateralis of IR and IS groups. A: Representative image of Oil red O stain (20 objective). B:
Representative image of immunostain for ﬁber type (20 objective). C: Pearson correlation of Rd with type I myocyte–speciﬁc IMTG content.
White data points  IS subjects; black data points  IR subjects. D: Pearson correlation of Rd with type II myocyte–speciﬁc IMTG content. White
data points  insulin sensitive; black data points  insulin resistant. E: IMTG content in type I myocytes, type II myocytes, and total IMTG in
vastus lateralis from IR and IS groups. *Signiﬁcantly different from IS, P < 0.05. AU, arbitrary units. (A high-quality color digital representation
of this ﬁgure is available in the online issue.)
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(35). Our data indicate that the proportion of type I and
type II myocytes is associated with higher ceramide con-
tent and insulin resistance and that the expression levels
of several genes related to mitochondrial biogenesis and
fatty acid metabolism are lower in insulin resistance.
Therefore, our complementary results support the concept
that a low oxidative capacity of muscle may be associated
with ceramide accumulation and insulin resistance. This is
consistent with previous reports that the increase in whole
muscle IMTG content in obesity or type 2 diabetes is
primarily due to increased IMTG in type I myocytes (25)
and that differences in ﬁber type proportion also play a
role in insulin resistance of obesity and type 2 diabetes
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FIG. 3. Gene expression in vastus lateralis of IR and IS subgroups. IR gene expression is expressed relative to IS group, which was set to a value
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reports suggesting that type I myocytes are more insulin
responsive than type II myocytes (26,27,38). Yet, differ-
ences in ﬁber type proportion between obese subjects
either with or without type 2 diabetes have been reported
in some (36,37), but not all previous studies (22,24).
Despite evidence in IR animal models supporting a role
for DAG in insulin resistance (8,9), we did not observe an
increased level of DAG in insulin-resistant muscle. Strac-
zkowski et al. (12) have also reported elevated levels of
ceramide, but not DAG, in obese impaired glucose tolerant
versus obese normal glucose tolerant (NGT) subjects. A
possible reason for lipid-induced insulin resistance by
ceramide and not DAG, and visa versa, may be that higher
levels of palmitate result in greater ceramide accumula-
tion, while unsaturated fatty acids partition toward DAG
(39). Thus, both ceramides and DAG can potentially
induce insulin resistance depending on the degree of
saturation of the lipid overload. Our ﬁnding that C16:0
ceramide was more than threefold higher in IR muscle is
consistent with this. Thus, it is plausible that basal levels
of ceramide and DAG in muscle are inﬂuenced by the
degree of saturation and palmitate content in the diet of
obese individuals. Further studies are needed to address
this attractive hypothesis.
We also examined the differential expression of several
other genes relating to lipid metabolism, which could
underlie accumulation of IMTG and other bioactive spe-
cies, i.e., DAG and ceramide. We found that many genes
involved in ceramide synthesis and degradation were not
differentially expressed in IR muscle with increased cer-
amide content. A recent report suggests that over expres-
sion of acid ceramidase prevents the inhibitory effect of
saturated fatty acids on insulin signaling (40). Also, inhi-
bition of serine palmitoyltranseferase in Zucker diabetic
fatty (ZDF) rats, by treatment with the amino acid antibi-
otic myriocin, prevented the onset of type 2 diabetes and
inhibited an increase in ceramide content in muscle, when
compared with nontreated ZDF rats (41). Our results
suggest that factors other than increased enzyme content,
possibly increased enzyme activity or fatty acid ﬂux,
contribute to ceramide accumulation in IR muscle. In
support of this, Straczkowski et al. (12) demonstrated that
the activity of neutral sphingomyelinase, the enzyme that
converts sphingomyelin to ceramide, is increased in mus-
cle of obese impaired glucose tolerant subjects compared
with obese normal glucose tolerant subjects, concomitant
with higher ceramide content. Finally, the observation that
gene expression of TNF-
 tended to be elevated in IR
muscle, albeit statistically nonsigniﬁcant, concomitant
with elevated ceramide content is consistent with data
demonstrating that TNF-
 can stimulate de novo ceramide
biosynthesis (42).
To further characterize intramyocellular lipid content
and metabolism in IR skeletal muscle, we determined the
expression of selected genes coding for lipid droplet
proteins and proteins involved in lipid droplet hydrolysis.
ATGL and HSL expression/activity have been demon-
strated to contribute to adipose tissue and skeletal muscle
triacylglycerol lipolysis, elevated plasma fatty acid levels,
and accumulation of ectopic lipid deposits associated with
type 2 diabetes (43). Our observation that ATGL and HSL
mRNA are lower in IR muscle is in line with reports of
lower expression of these lipases in obesity and/or insulin
resistance (44,45). We also found lower expression of
ADRP in IR muscle. Consistent with this, Phillips et al.
showed that skeletal muscle protein expression of ADRP
was upregulated in response to improvements in insulin
action induced by weight loss and insulin sensitizer phar-
macotherapy (46). Furthermore, ATGL and ADRP have
been reported to be more highly expressed in type I
muscle ﬁbers (47,48). The ﬁber type–speciﬁc expression of
ATGL and ADRP, and our observation of reduced type I
ﬁbers in obese IR subjects, potentially explains the lower
level of ATGL and ADRP observed in whole muscle in the
present study. It is tempting to speculate the same may be
true for other lipases and that ﬁber type composition plays
a greater role in insulin resistance than previously thought.
Furthermore, the trend toward higher TNF-
 gene expres-
sion in IR muscle is in line with reports that TNF-

represses ATGL expression (49). We also observed for the
ﬁrst time in human muscle that the expression of SNAP23,
a member of the SNARE family of proteins whose function
is to mediate intracellular vesicle fusion events including
GLUT4 transport to the plasma cell membrane and lipid
droplet fusion (50), is lower in IR muscle. This novel
ﬁnding potentially linking intramyocellular lipid droplets
and glucose transport is supported by others describing an
association between SNAP23 and fatty acid–induced insu-
lin resistance (50).
Future studies should be conducted to examine whether
or not interventions such as exercise or weight loss affect
oxidative capacity, DAG, ceramide, and insulin sensitivity
to better understand these associations in humans. Al-
though we substantiated our insulin resistance phenotype
with expression of key genes involved in insulin signaling
and glucose transport, additional studies are needed to
link intramyocellular lipids, ﬁber type, oxidative capacity,
and activation of speciﬁc insulin-signaling proteins. Taken
together, however, these results suggest a role for muscle
ﬁber type proportion and/or the oxidative capacity of
muscle in insulin resistance, possibly through partitioning
muscle lipids into either triglycerides or ceramides.
In summary, ceramide but not diacylglycerol is elevated
in IR human skeletal muscle independent of obesity,
physical activity, or aerobic ﬁtness. Moreover, muscle
ﬁber type as well as ﬁber type–speciﬁc lipid content is
associated with insulin resistance in muscle. Importantly,
key genes associated with fatty acid metabolism and lipid
droplet regulation are decreased in IR muscle. Together,
these data suggest that mechanisms underlying the asso-
ciations between intramyocellular lipids and insulin resis-
tance likely involve ceramide, which in turn may depend
on the muscle ﬁber type or its oxidative capacity. Future
mechanistic studies are needed to further elucidate these
important ﬁndings.
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